Conference: 2026 SNMMI Annual Meeting
Date: May 30 - June 2, 2026
Location: Los Angeles, CA
Booth: 533
Mirjam Trame, PharmD, PhD
VP, Certara Drug Development Solutions, Head of Pharmacometrics USA – Division IIMirjam is an expert in pharmacometrics and oncology drug development, serving as Head of Pharmacometrics USA – Division II at Certara Drug Development Solutions. With expertise spanning complex biologics, she supports exposure-response analysis, dose and study optimization, and regulatory strategy, with a special focus on radiotherapeutics and cell and gene therapies.
Hunter Stephens, PhD
Associate DirectorHunter Stephens, PhD, is an Associate Director in the Pharmacometrics group at Certara. He specializes in applying mathematical and computational models to understand the pharmacokinetics and pharmacodynamics of drugs, especially radiopharmaceuticals. He has a PhD in Medical Physics from Duke University. He also holds an MS in Physics from North Carolina State University and a BS in Mathematics from Tennessee Tech University. His work in TRT has focused on building semi-mechanistic population PK models to simulate and predict absorbed and biologically effective doses to inform dose-range finding and questions of safety and efficacy. In addition, he has extensive experience in radiation dosimetry from external and internal sources.
Joshuaine Grant
Sr. Director, QSPJoshuaine Grant is a Senior Director in Quantitative Systems Pharmacology at Certara with more than 25 years of experience integrating biophysics, disease biology, and quantitative modeling to advance drug development. She leads collaborative projects that use mechanistic and translational QSP modeling to inform key decisions from discovery through the clinic. Her broad experience across biologics and complex therapeutics has supported Certara’s growing leadership in radioligand and targeted radiotherapies.
Amandine Manon, PharmD
Senior Director, Clinical Pharmacology and Translational MedicineAmandine joined Certara in 2020. She served as a Clinical pharmacologist in several pharmaceutical companies for 15 years. She has a proven track record in preclinical and clinical PK, clinical pharmacology with a special focus on oncology, drug development from early stages to Phase 3, and regulatory experience. Amandine graduated as a PharmD from Paris University, France and she also holds a Master’s degree in Pharmacokinetics.
Global Account Director
Based in San Diego, Bill is a Director of Business Development for the West Coast. Leveraging extensive nonclinical experience, he helps clients utilize Certara’s services from predictive modeling to market access strategies to enhance their decision-making. Bill is dedicated to making every drug the safer bet.
Where to hear Certara insights and expertise
Session Time: 11:30 AM - 12:15 PM
Session Name: Oncology: Discovery & Translational Meet the Author Session
Abstract # – Session # – Screen #: #261716 – MTA11 – Screen 56
Authors: Sarah Minucci, Jamie Nosbisch, Bhabuk Koirola, Ben Lang, Joshuaine Grant
Presenter: Joshuaine Grant
Session Time: 8:30 AM - 9:15 PM
Session Name: PIDS Meet the Author Session One
Abstract # – Session # – Screen #: #262011- MTA05 – Screen 39
Authors: Hunter Stephens, Amandine Manon, Mirjam N. Trame
Presenter: Hunter Stephens
Connect with Certara’s experts at SNMMI to explore how modeling, clinical pharmacology, and quantitative approaches support confident decision-making in radiopharmaceutical and targeted radiotherapy development, from early clinical strategy through regulatory submission.
Schedule time with our team to discuss your program and key challenges such as first-in-human activity selection, dosimetry strategy, and dose optimization.
